Caleb Paasche

Caleb Paasche is an associate in the firm’s Business Law department. He joined Goodwin in 2024.

• Represented the underwriters in VSE Corporation’s $460 million follow-on public offering.
• Represented the underwriters in a $60 million follow-on offering of Vertical Aerospace ordinary shares.
• Represented the company in Larimar Therapeutics’ $69 million underwritten public offering of common stock.
• Represented a private company in its Series A preferred stock financing of approximately $19 million.
• Represented Ikena Oncology in the company’s reverse merger and concurrent $75 million oversubscribed PIPE with Inmagene Bio.
• Represented the company in Lifeward’s $2.6 million follow-on offering of ordinary shares and pre-funded warrants.
• Represented the company in Ocugen’s $22.5 million registered direct offering of common stock.
• Represented the company in Altimmune’s $75 million registered direct offering of common stock and pre-funded warrants.
• Represented the underwriters in VSE Corporation’s $1.3 billion follow-on public offering of common stock and tangible equity units.
• Represented the company in The Metals Royalty Company’s direct listing of approximately 55 million shares.
• Represented the company in Altimmune’s $225 million follow-on offering of common stock, warrants, and pre-funded warrants.
• Represented the company in Relay Therapeutics’ $316 million underwritten public offering of common stock.
• Represented the underwriters in a $35 million follow-on offering of Vertical Aerospace’s ordinary shares.

While attending New York University School of Law, Caleb was on the Annual Survey of American Law journal. He was also president of the school’s Sports Law Association.

Prior to law school, Caleb worked at The Margolis Law Firm as an Immigration paralegal.